BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35381344)

  • 21. Genital chronic graft-versus-host disease in females: a cross-sectional study.
    Smith Knutsson E; Björk Y; Broman AK; Helström L; Levin Jakobsen AM; Nilsson O; Sundfeldt K; Brune M
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):806-11. PubMed ID: 24594123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The predictive value of serum free light chain level early after allogeneic hematopoietic stem cell transplantation for chronic graft-versus-host disease, a preliminary study.
    Wang B; Liang Z; Liu W; Sun Y; Cen X; Dong Y; Ren H
    Clin Transplant; 2020 Jul; 34(7):e13865. PubMed ID: 32242991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
    Chen CT; Liu CY; Yu YB; Liu CJ; Hsiao LT; Gau JP; Chiou TJ; Liu JH; Liu YC
    PLoS One; 2017; 12(9):e0185210. PubMed ID: 28934311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
    Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.
    Fall-Dickson JM; Mitchell SA; Marden S; Ramsay ES; Guadagnini JP; Wu T; St John L; Pavletic SZ;
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):948-956. PubMed ID: 20139026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymyositis after donor lymphocyte infusion.
    Montoro J; Hernández-Boluda JC; Arbona C; Solano C
    Int J Hematol; 2012 Sep; 96(3):386-9. PubMed ID: 22903864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease.
    Ljubas Kelecic D; Lelas A; Karas I; Desnica L; Vukic T; Sabol I; Vranesic Bender D; Serventi Seiwerth R; Peric Z; Durakovic N; Vitali Cepo D; Vrhovac R; Nemet D; Pavletic S; Pulanic D; Krznaric Z
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2967-2978. PubMed ID: 32507973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease.
    Allen JA; Greenberg SA; Amato AA
    Muscle Nerve; 2009 Oct; 40(4):643-7. PubMed ID: 19670319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral Complications of Chronic Graft-Versus-Host Disease.
    Fall-Dickson JM; Pavletic SZ; Mays JW; Schubert MM
    J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
    Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
    Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
    Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical digital ischemia and biliary cholangitis related to graft versus host disease: A case report and systematic literature review.
    Hidalgo Calleja C; Montilla Morales CA; Sánchez González MD; Pastor Navarro S; Ibáñez Martínez M; Conde Ferreiros A; López Corral L
    Medicine (Baltimore); 2023 Jan; 102(2):e32495. PubMed ID: 36637943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
    Zeiser R
    J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
    [No Abstract]   [Full Text] [Related]  

  • 36. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
    Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
    Front Immunol; 2019; 10():1879. PubMed ID: 31507582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease.
    Akpek G; Lee SM; Anders V; Vogelsang GB
    Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three US Food and Drug Administration-approved therapies for chronic GVHD.
    Zeiser R; Lee SJ
    Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genital chronic GVHD in men after hematopoietic stem cell transplantation: a single-center cross-sectional analysis of 155 patients.
    Mueller SM; Haeusermann P; Rovó A; Halter JP; Passweg J; Itin P; Tichelli A
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1574-80. PubMed ID: 23962394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
    Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.